Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 07:18:47 2026-07-17 am EDT			5-day change	1st Jan Change
333.18 ^DKK	-0.78%		+3.52%	+2.57%

05:38am	US companies face rise in cyber attacks	RE
05:36am	US companies face rise in cyber attacks	RE

Veru to Conduct Enobosarm Clinical Study With Novo Nordisk's Weight-Loss Pill Wegovy

Published on 06/04/2026 at 01:53 pm EDT

Dow Jones

Add MarketScreener to your sources

NOVO NORDISK A/S

-0.78%

VERU INC.

-2.89%

By Elias Schisgall

Veru agreed to conduct a clinical study of one of its treatments in combination with Novo Nordisk's Wegovy weight loss drug.

Under the terms of a supply agreement with Novo, Veru will conduct and sponsor a Phase 2b study to test the combination of Wegovy and enobosarm, a selective androgen receptor modulator developed by Veru, in older adults with obesity. Novo will supply Wegovy at no cost.

Veru also granted Novo a right of first negotiation if the company decides to develop, commercialize, or license enobosarm in combination with any of Novo's GLP-1 products, including Wegovy.

Shares of Veru soared on the news, gaining more than one-and-a-half times their value and trading at $5.74 Thursday. The stock has nearly tripled in value this year.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

06-04-26 1352ET

Add MarketScreener to your sources

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Off-Hours Price	Change	5-day change	Capi.
	NOVO NORDISK A/S	333.18DKK	-0.78%	+3.52%	227B
	VERU INC.	2.350USD	-2.89%	-16.37%	37.72M

Latest news about Novo Nordisk A/S

05:38am	US companies face rise in cyber attacks	RE
05:36am	US companies face rise in cyber attacks	RE
04:36am	India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease	RE
12:55am	Nordic stocks in North America - Astra Zeneca fell 0.3%	FW
Jul. 16	European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday	MT
Jul. 16	Länsförsäkringar Sverige Vision rose 1.56 percent in June, overweight positions in Essity and Novo Nordisk contributed the most positively	FW
Jul. 16	Handelsbanken raises its target price for Novo Nordisk to 365 Danish kroner (350), reiterates buy	FW
Jul. 16	United Laboratories Unit Receives $13.5 Million Milestone Payment From Novo Nordisk	MT
Jul. 16	Nordic stocks in North America, Autoliv fell 1.6 percent	FW
Jul. 16	Novo Nordisk: EU approves Wegovy in tablet form	FW
Jul. 15	Novo Nordisk Gets Regulatory Nod to Market Weight Loss Pill in EU	MT
Jul. 15	Novo Nordisk Receives European Commission Approval of Wegovy® Pill as First Oral Glp-1 for Weight Management in the Eu; Single, Ready-To-Use Pen for Higher Dose 7.2 Mg Also Approved	CI
Jul. 15	Novo Nordisk Gets EU Approval for Wegovy Pill for Weight Management	MT
Jul. 15	Chip-Machine Supplier ASML Raises Guidance Again on Unrelenting AI Demand -- 5th Update	DJ
Jul. 15	Novo Nordisk wins EU approval for Wegovy weight-loss pill	RE

Chart Novo Nordisk A/S

Duration

Period

NOVO B: Dynamic Chart

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

67,900

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company